APA (7th ed.) Citation

Leubitz, A., Frydman‐Marom, A., Sharpe, N., Duzer, J., Campbell, K. C., & Vanhoutte, F. (2019). Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers. Clinical pharmacology in drug development, 8(8), 984-994. https://doi.org/10.1002/cpdd.647

Chicago Style (17th ed.) Citation

Leubitz, Andi, Anat Frydman‐Marom, Neal Sharpe, John Duzer, Kathleen C.M Campbell, and Frédéric Vanhoutte. "Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers." Clinical Pharmacology in Drug Development 8, no. 8 (2019): 984-994. https://doi.org/10.1002/cpdd.647.

MLA (9th ed.) Citation

Leubitz, Andi, et al. "Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers." Clinical Pharmacology in Drug Development, vol. 8, no. 8, 2019, pp. 984-994, https://doi.org/10.1002/cpdd.647.